These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 30410613)

  • 1. Impact of the Time Interval from Neoadjuvant Chemotherapy to Surgery in Primary Ovarian, Tubal, and Peritoneal Cancer Patients.
    Chen M; Chen Z; Xu M; Liu D; Liu T; He M; Yao S
    J Cancer; 2018; 9(21):4087-4091. PubMed ID: 30410613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
    Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
    Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
    J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From the completion of neoadjuvant chemotherapy to surgery for colorectal cancer liver metastasis: What is the optimal timing?
    Chen Q; Mao R; Zhao J; Bi X; Li Z; Huang Z; Zhang Y; Zhou J; Zhao H; Cai J
    Cancer Med; 2020 Nov; 9(21):7849-7862. PubMed ID: 32886456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.
    Bixel K; Vetter M; Davidson B; Berchuck A; Cohn D; Copeland L; Fowler JM; Havrilesky L; Lee PS; O'Malley DM; Salani R; Valea F; Alvarez Secord A; Backes F
    Gynecol Oncol; 2020 Mar; 156(3):530-534. PubMed ID: 31937450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
    Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical treatment pattern and outcomes in epithelial ovarian cancer patients from a cancer institute in Kerala, India.
    Georgeena P; Rajanbabu A; Vijaykumar DK; Pavithran K; Sundaram KR; Deepak KS; Sanal MR
    Ecancermedicalscience; 2016; 10():619. PubMed ID: 26913070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timing is everything: intraperitoneal chemotherapy after primary or interval debulking surgery for advanced ovarian cancer.
    Lee J; Curtin JP; Muggia FM; Pothuri B; Boyd LR; Blank SV
    Cancer Chemother Pharmacol; 2018 Jul; 82(1):55-63. PubMed ID: 29704010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.
    Rauh-Hain JA; Rodriguez N; Growdon WB; Goodman AK; Boruta DM; Horowitz NS; del Carmen MG; Schorge JO
    Ann Surg Oncol; 2012 Mar; 19(3):959-65. PubMed ID: 21994038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Laparoscopy to Assess Resectability in Stage IIIC Epithelial Ovarian, Tubal and Peritoneal Cancer Patients.
    Sánchez-Iglesias JL; Perez-Benavente A; Correa-Paris A; De la Torre Fernandez de Vega J; Carbonell Socias M; Gil-Moreno A
    Gynecol Obstet Invest; 2019; 84(3):259-267. PubMed ID: 30428466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
    Mueller JJ; Zhou QC; Iasonos A; O'Cearbhaill RE; Alvi FA; El Haraki A; Eriksson AG; Gardner GJ; Sonoda Y; Levine DA; Aghajanian C; Chi DS; Abu-Rustum NR; Zivanovic O
    Gynecol Oncol; 2016 Mar; 140(3):436-42. PubMed ID: 26777991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of Interval Between the Initiation of Neoadjuvant Treatment to Surgery for Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemotherapy, Radiotherapy and Definitive Surgery.
    Wan XB; Zhang Q; Chen M; Liu Y; Zheng J; Lan P; He F
    Front Oncol; 2020; 10():1280. PubMed ID: 32974129
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical outcome of Iranian patients with advanced ovarian cancer with neoadjuvant chemotherapy versus primary debulking surgery.
    Ghaemmaghami F; Karimi-Zarchi M; Modares-Gilani M; Mousavi A; Behtash N
    Asian Pac J Cancer Prev; 2008; 9(4):719-24. PubMed ID: 19256766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).
    Chi DS; Musa F; Dao F; Zivanovic O; Sonoda Y; Leitao MM; Levine DA; Gardner GJ; Abu-Rustum NR; Barakat RR
    Gynecol Oncol; 2012 Jan; 124(1):10-4. PubMed ID: 21917306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer.
    Chen JB; Liu ZN; Wang YK; Shan F; Li SX; Jia YN; Xue K; Miao RL; Li ZM; Wu ZQ; Ying XJ; Zhang Y; Li ZY; Ji JF
    Front Oncol; 2022; 12():956706. PubMed ID: 36620591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC.
    Biacchi D; Accarpio F; Ansaloni L; Macrì A; Ciardi A; Federici O; Spagnoli A; Cavaliere D; Vaira M; Sapienza P; Sammartino P
    J Surg Oncol; 2019 Dec; 120(7):1208-1219. PubMed ID: 31531879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What is the optimal treatment for obese patients with advanced ovarian carcinoma?
    Worley MJ; Guseh SH; Rauh-Hain JA; Esselen KM; Muto MG; Feltmate CM; Berkowitz RS; Del Carmen MG; Schorge JO; Horowitz NS
    Am J Obstet Gynecol; 2014 Sep; 211(3):231.e1-9. PubMed ID: 24704062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.
    da Costa Miranda V; de Souza Fêde ÂB; Dos Anjos CH; da Silva JR; Sanchez FB; da Silva Bessa LR; de Paula Carvalho J; Filho EA; de Freitas D; Del Pilar Estevez Diz M
    Gynecol Oncol; 2014 Feb; 132(2):287-91. PubMed ID: 24333355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple Cycles of Neoadjuvant Chemotherapy Associated With Poor Survival in Bulky Stage IIIC and IV Ovarian Cancer.
    Ren Y; Shi T; Jiang R; Yin S; Wang P; Zang R
    Int J Gynecol Cancer; 2015 Oct; 25(8):1398-404. PubMed ID: 26222486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Survival Between Primary Debulking Surgery Versus Neoadjuvant Chemotherapy for Ovarian Cancers in a Personalized Treatment Cohort.
    Feng Z; Wen H; Li R; Liu S; Fu Y; Chen X; Bi R; Ju X; Wu X
    Front Oncol; 2020; 10():632195. PubMed ID: 33643924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.